Top Markets
Coin of the day
BerGenBio ASA BerGenBio ASA

BerGenBio ASA

BGBIO
Peringkat dalam Saham #37880
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage,... BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
Harga Saham
$0.051239
Terakhir disinkronkan: 2025-11-24
Kapitalisasi Pasar
$1.38M
Perubahan (1 hari)
-4.48%
Perubahan (1 tahun)
-54.57%
Negara
NO
Perdagangan BerGenBio ASA (BGBIO)

Kategori

Riwayat hasil dividen untuk BerGenBio ASA (BGBIO)
Hasil dividen (TTM) dari BerGenBio ASA (simbol saham: BGBIO) per 2026: 0
Rata-rata hasil dividen selama 5 tahun terakhir: 0.00%
Riwayat hasil dividen untuk BerGenBio ASA (BGBIO) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
Tahun Hasil Dividen Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing